{"id":550960,"date":"2022-09-24T08:49:31","date_gmt":"2022-09-24T06:49:31","guid":{"rendered":"https:\/\/www.hashtag.al\/?p=550960"},"modified":"2022-09-24T08:49:31","modified_gmt":"2022-09-24T06:49:31","slug":"mungesa-e-ilaceve-po-vret-shqiperia-nuk-ka-akses-ne-terapite-e-reja-inovative","status":"publish","type":"post","link":"https:\/\/www.hashtag.al\/index.php\/2022\/09\/24\/mungesa-e-ilaceve-po-vret-shqiperia-nuk-ka-akses-ne-terapite-e-reja-inovative\/","title":{"rendered":"Mungesa e ila\u00e7eve po \u201cvret\u201d; Shqip\u00ebria nuk ka akses n\u00eb terapit\u00eb e reja inovative","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

\"\"<\/a><\/span><\/p>\n

Kanceri dhe s\u00ebmundjet e rralla \u201cvrasin\u201d mij\u00ebra persona gjat\u00eb nj\u00eb viti, edhe p\u00ebr shkak se, Shqip\u00ebria nuk ka akses n\u00eb terapit\u00eb e reja inovative q\u00eb trajtojn\u00eb k\u00ebto s\u00ebmundje. Nga viti 2017 deri n\u00eb vitin 2020, Shqip\u00ebria p\u00ebrfshiu n\u00eb list\u00ebn e rimbursimit vet\u00ebm 5 barna t\u00eb reja nga 160 t\u00eb tilla q\u00eb hyn\u00eb n\u00eb p\u00ebrdorim n\u00eb vendet Europ\u00ebs. P\u00ebr trajtimin e s\u00ebmundjeve t\u00eb rralla, n\u00eb k\u00ebt\u00eb periudh\u00eb Shqip\u00ebria nuk p\u00ebrfshiu asnj\u00eb medikament t\u00eb ri n\u00eb list\u00ebn e rimbursimit, nd\u00ebrsa vendet n\u00eb Europ\u00eb, 57 barna. Statistikat tregojn\u00eb p\u00ebr nj\u00eb p\u00ebrhapje t\u00eb shpejt\u00eb t\u00eb kancerit dhe barr\u00ebs s\u00eb s\u00ebmundjeve, por fondet p\u00ebr rimbursimin mbeten n\u00eb vendnum\u00ebro.<\/span><\/p>\n

Si nj\u00eb vend ku varf\u00ebria \u00ebsht\u00eb e pranishme n\u00eb 30% t\u00eb popullsis\u00eb dhe buxheti publik ka kapacitete t\u00eb kufizuara p\u00ebr sh\u00ebndet\u00ebsin\u00eb, pacient\u00ebt shqiptar\u00eb vuajn\u00eb nga mungesa t\u00eb thella t\u00eb terapive inovative q\u00eb do t\u00eb mund t\u00eb shp\u00ebtonin mij\u00ebra jet\u00eb, sidomos nga zbulimi dhe trajtimi n\u00eb koh\u00eb i neoplazmave.<\/span><\/p>\n

Nga viti 2017 deri n\u00eb vitin 2020, Bashkimi Europian ka miratuar rreth 160 barna t\u00eb reja q\u00eb trajtojn\u00eb s\u00ebmundje t\u00eb ndryshme, por n\u00eb Shqip\u00ebri, gjat\u00eb s\u00eb nj\u00ebjt\u00ebs periudh\u00eb jan\u00eb p\u00ebrfshir\u00eb vet\u00ebm 5 prej tyre n\u00eb listat e rimbursimit.<\/span><\/p>\n

Nj\u00eb studim i fundit i IQVIA (kompani shum\u00ebkomb\u00ebshe q\u00eb u sh\u00ebrben industrive t\u00eb kombinuara t\u00eb teknologjis\u00eb s\u00eb informacionit sh\u00ebndet\u00ebsor dhe k\u00ebrkimit klinik) gjeti se Shqip\u00ebria ka pranin\u00eb m\u00eb t\u00eb ul\u00ebt t\u00eb medikamenteve t\u00eb reja, me nj\u00eb diferenc\u00eb shum\u00eb t\u00eb madhe me fqinj\u00ebt si Maqedonia e Veriut, Serbia, t\u00eb cilat kan\u00eb miratuar p\u00ebrkat\u00ebsisht 11 dhe 17 medikamente t\u00eb reja secila.<\/span><\/p>\n

Burimet nga Shoqata e Farmacist\u00ebve t\u00eb Shqip\u00ebris\u00eb than\u00eb se, mungesa n\u00eb tregun e medikamenteve t\u00eb reja lidhet me fondet e ul\u00ebta buxhetore p\u00ebr rimbursimin e tyre. Zakonisht k\u00ebto medikamente jan\u00eb t\u00eb kushtueshme dhe shtetet i p\u00ebrfshijn\u00eb n\u00eb list\u00ebn e rimbursimit.<\/span><\/p>\n

Kompanit\u00eb nuk jan\u00eb t\u00eb interesuara t\u2019i sjellin k\u00ebto barna n\u00eb treg, n\u00ebse nuk jan\u00eb t\u00eb p\u00ebrfshira n\u00eb rimbursim, pasi n\u00eb t\u00eb gjith\u00eb bot\u00ebn, shp\u00ebrndarja e tyre te pacient\u00ebt mbulohet nga buxheti publik.<\/span><\/p>\n

Studimi i IQVIA tregon se nga 160 medikamentet e reja q\u00eb u miratuan p\u00ebr p\u00ebrdorim, 74 prej tyre, ose rreth 46%, jan\u00eb n\u00eb dispozicion t\u00eb pacient\u00ebve n\u00eb BE, nd\u00ebrsa n\u00eb Shqip\u00ebri, vet\u00ebm 3% e tyre n\u00eb dispozicion.<\/span><\/p>\n

Agjencia Komb\u00ebtare e Barnave dhe Pajisjeve Mjek\u00ebsore, n\u00eb nj\u00eb shpjegim t\u00eb posa\u00e7\u00ebm evidentoi se, q\u00eb nga viti 2017 deri n\u00eb vitin 2020 ka dh\u00ebn\u00eb Autorizim p\u00ebr Tregtimin n\u00eb Republik\u00ebn e Shqip\u00ebris\u00eb, p\u00ebr rreth 194 barna antitumorale, p\u00ebrfshir\u00eb k\u00ebtu edhe 10 barna \u201cOrphan\u201d, n\u00ebp\u00ebrmjet Procedur\u00ebs s\u00eb P\u00ebrshpejtuar, 30 dit\u00eb nga data e aplikimit.<\/span><\/p>\n

Por Shoqata e Farmacist\u00ebve t\u00eb Shqip\u00ebris\u00eb shpjegoi se regjistrimi i produkteve farmaceutike nuk do t\u00eb thot\u00eb se mund t\u00eb gjenden n\u00eb treg. Kostoja e mujore e nj\u00eb medikamenti t\u00eb ri i kalon 500 euro n\u00eb muaj dhe aft\u00ebsia p\u00ebr ta bler\u00eb at\u00eb n\u00eb treg t\u00eb lir\u00eb \u00ebsht\u00eb vet\u00ebm p\u00ebr pacient\u00eb q\u00eb num\u00ebrohen me gishtat e dor\u00ebs, teksa kan\u00eb nevoj\u00eb mjekimi mij\u00ebra persona.<\/span><\/p>\n

\u201cBari b\u00ebhet i p\u00ebrdorsh\u00ebm, kur ai p\u00ebrfshihet n\u00eb list\u00ebn e rimbursimit. Shqip\u00ebria e ka fondin e rimbursimit t\u00eb medikamenteve vet\u00ebm 100 milion\u00eb dollar\u00eb n\u00eb muaj, nd\u00ebrsa vendet e rajonit dhe Europ\u00ebs, deri n\u00eb 10-fish m\u00eb t\u00eb lart\u00eb\u201d<\/em>, sqaroi shoqata.<\/span><\/p>\n

M\u00eb tej, shoqata shpjegoi se, p\u00ebrdorimi i barnave t\u00eb reja p\u00ebr pacient\u00ebt shqiptar\u00eb mund\u00ebsohet nga lista e rimbursimit, e cila administrohet nga Fondi i Sigurimeve t\u00eb Detyrueshme Sh\u00ebndet\u00ebsore (FSDKSH). Por FSDKSH nuk iu p\u00ebrgjigj interesit n\u00eb lidhje me struktur\u00ebn e buxhetit t\u00eb sigurimeve sh\u00ebndet\u00ebsore dhe p\u00ebrfshirjen n\u00eb list\u00eb t\u00eb terapive t\u00eb reja, deri n\u00eb momentin kur u shkrua ky artikull.<\/span><\/p>\n

P\u00ebr shkak se tregu i ila\u00e7eve t\u00eb kushtueshme lidhet n\u00eb m\u00ebnyr\u00eb t\u00eb drejtp\u00ebrdrejt\u00eb me list\u00ebn e rimbursimit, kompanit\u00eb e m\u00ebdha t\u00eb farmaceutik\u00ebs jan\u00eb duke rishikuar pozicionin e tyre n\u00eb Shqip\u00ebri, me perspektiv\u00eb mbylljen e filialeve.<\/span><\/p>\n

Fondi i rimbursimit t\u00eb medikamenteve k\u00ebt\u00eb vit \u00ebsht\u00eb rreth 11 miliard\u00eb lek\u00eb.<\/span><\/p>\n

Buxheti i Fondit t\u00eb Sigurimit Sh\u00ebndet\u00ebsor \u00ebsht\u00eb rritur vit pas viti, por ritmet e rritjes nuk kan\u00eb qen\u00eb t\u00eb nj\u00ebjta p\u00ebr fondin e rimbursimit t\u00eb medikamenteve. N\u00eb vitin 2019, fondet p\u00ebr rimbursimin e barnave zinin 27% t\u00eb buxhetit total t\u00eb sigurimeve sh\u00ebndet\u00ebsore, nd\u00ebrsa n\u00eb vitin 2022, ato jan\u00eb planifikuar t\u00eb z\u00ebn\u00eb vet\u00ebm 23% t\u00eb buxhetit total t\u00eb sigurimeve.<\/span><\/p>\n

Buxheti i Fondit t\u00eb Sigurimeve t\u00eb Detyrueshme Sh\u00ebndet\u00ebsore (FSDKSH) \u00ebsht\u00eb rritur vit pas viti, por rritja m\u00eb s\u00eb shumti ka shkuar p\u00ebr financimin e kontratave me Partneritet Publik-Privat, si kontrolli mjek\u00ebsor baz\u00eb (check-up, sterilizimi i mjeteve kirurgjikale, dializa dhe s\u00eb fundmi laboratori). N\u00eb vitin 2020, shpenzimet p\u00ebr pagesat e koncesioneve zun\u00eb 4.6% t\u00eb shpenzimeve totale t\u00eb Fondit t\u00eb Sigurimeve.<\/span><\/p>\n

\"\"<\/a><\/span><\/strong><\/p>\n

Barnat e reja, rrug\u00eb t\u00eb gjat\u00eb p\u00ebr te pacienti shqiptar<\/span><\/strong><\/p>\n

Q\u00eb kur nis marketimi i nj\u00eb ila\u00e7i t\u00eb ri deri sa t\u00eb dal\u00eb n\u00eb tregje, k\u00ebrkohet nj\u00eb periudh\u00eb kohe q\u00eb kryesisht ka t\u00eb b\u00ebj\u00eb me procedurat e regjistrimit q\u00eb aplikon secili shtet dhe interesin q\u00eb kan\u00eb kompanit\u00eb farmaceutike p\u00ebr k\u00ebto barna. Studimi i IQVA tregon se, Shqip\u00ebria klasifikohet nd\u00ebr vendet ku k\u00ebrkohet koh\u00eb m\u00eb e gjat\u00eb p\u00ebr hyrjen e nj\u00eb medikamenti n\u00eb treg. Q\u00eb nga momenti i marketimit deri n\u00eb raftet e farmacis\u00eb, nevojiten 882 dit\u00eb, rreth 2 vite e 4 muaj.<\/span><\/p>\n

Nga 39 vendet europiane n\u00eb studim, Shqip\u00ebria l\u00eb pas vet\u00ebm Rumanin\u00eb me 899 dit\u00eb. T\u00eb dh\u00ebnat tregojn\u00eb se vendet e zhvilluara t\u00eb Europ\u00ebs kan\u00eb nj\u00eb fleksibilitet t\u00eb lart\u00eb t\u00eb aksesit t\u00eb barnave t\u00eb reja n\u00eb tregje. P.sh., Gjermanis\u00eb i duhen vet\u00ebm 133 dit\u00eb q\u00eb t\u00eb v\u00ebr\u00eb n\u00eb dispozicion t\u00eb qytetar\u00ebve t\u00eb saj nj\u00eb terapi t\u00eb re mjekimi, Danimark\u00ebs 176 dit\u00eb.<\/span><\/p>\n

E treta n\u00eb Europ\u00eb p\u00ebr shpejt\u00ebsin\u00eb e lejimit t\u00eb medikamenteve t\u00eb reja \u00ebsht\u00eb shteti fqinj, Maqedonia e Veriut, me vet\u00ebm 191 dit\u00eb, m\u00eb pas Rusia etj. N\u00eb shumic\u00ebn e vendeve, disponueshm\u00ebria barazohet me dh\u00ebnien e aksesit n\u00eb list\u00ebn e rimbursimit, p\u00ebrve\u00e7se n\u00eb disa vende produktet spitalore nuk mbulohen nga skema e p\u00ebrgjithshme e rimbursimit.<\/span><\/p>\n

N\u00eb Mbret\u00ebrin\u00eb e Bashkuar, Skema e Qasjes s\u00eb Hershme n\u00eb Barna t\u00eb MHRA ofron akses para autorizimit t\u00eb marketingut.<\/span><\/p>\n

Agjencia Komb\u00ebtare e Barnave dhe Pajisjeve Mjek\u00ebsore, sqaroi se, n\u00eb asnj\u00eb rast, regjistrimi i barnave n\u00eb RSH nuk kalon afatin 210 dit\u00eb, ashtu sikurse \u00ebsht\u00eb parashikuar n\u00eb VKM dhe n\u00eb direktiv\u00ebn e Parlamentit Europian. Por Shoqata e Farmacist\u00ebve shpjegon se vonesat lidhen me faktin e mosp\u00ebrfshirjes n\u00eb list\u00ebn e rimbursimit. \u201cKompanit\u00eb kan\u00eb regjistruar dhjet\u00ebra terapi t\u00eb reja, por ato nuk jan\u00eb t\u00eb aksesueshme p\u00ebr shkak se duhet t\u00eb mbulohen nga listat e rimbursimit\u201d \u2013 reagoi Shoqata e Farmacist\u00ebve.<\/span><\/p>\n

P\u00ebrmir\u00ebsimi i disponueshm\u00ebris\u00eb s\u00eb barnave t\u00eb autorizuara n\u00eb Bashkimin Europian (BE) \u00ebsht\u00eb nj\u00eb prioritet ky\u00e7 p\u00ebr rrjetin rregullator europian t\u00eb barnave dhe industrin\u00eb farmaceutike.<\/span><\/p>\n

\"\"<\/a><\/span><\/strong><\/p>\n

41 medikamente t\u00eb reja kund\u00ebr kancerit n\u00eb Europ\u00eb, vet\u00ebm dy n\u00eb Shqip\u00ebri<\/span><\/strong><\/p>\n

Deri m\u00eb 1 janar t\u00eb vitit 2022, Bashkimi Europian dhe autoritetet rregullatore autorizuan 41 terapi t\u00eb reja p\u00ebr trajtimin e s\u00ebmundjeve onkologjike (kancerit), por n\u00eb Shqip\u00ebri jan\u00eb t\u00eb pranishme n\u00eb list\u00ebn e rimbursimit vet\u00ebm dy prej tyre, evidentoi studimi i IQVIA.<\/span><\/p>\n

Shqip\u00ebria, Kazakistani dhe Malta u rendit\u00ebn t\u00eb fundit p\u00ebr aksesin e ul\u00ebt n\u00eb medikamentet novatore q\u00eb trajtojn\u00eb neoplazmat. Maqedonia e Veriut ka p\u00ebrfshir\u00eb n\u00eb list\u00ebn e rimbursimit 6 terapi t\u00eb reja, Serbia, 8 terapi, Bosnja, 4 terapi (Mali i Zi dhe Kosova nuk jan\u00eb pjes\u00eb studimit).<\/span><\/p>\n

Shoqata e Farmacist\u00ebve shpjegoi se, k\u00ebto medikamente nuk jan\u00eb t\u00eb p\u00ebrfshira n\u00eb list\u00ebn e rimbursimit, prandaj pacient\u00ebt nuk kan\u00eb akses, pasi shumica e tyre e kan\u00eb t\u00eb pamundur t\u00eb p\u00ebrballojn\u00eb trajtime t\u00eb kushtueshme prej mij\u00ebra eurosh. Gjermania ishte vendi me aksesin m\u00eb t\u00eb lart\u00eb t\u00eb terapive t\u00eb reja kund\u00ebr kancerit, duke p\u00ebrfshir\u00eb n\u00eb list\u00ebn e rimbursimit 41 medikamenteve t\u00eb reja, m\u00eb pas Italia, me 37 medikamente t\u00eb p\u00ebrfshira n\u00eb list\u00eb etj.<\/span><\/p>\n

Kanceri \u00ebsht\u00eb nj\u00eb nga shkaqet kryesore t\u00eb vdekjeve n\u00eb bot\u00eb, megjithat\u00eb, Instituti i Sh\u00ebndetit Publik, n\u00eb nj\u00eb studim t\u00eb posa\u00e7\u00ebm vler\u00ebson se m\u00eb shum\u00eb se nj\u00eb e treta e k\u00ebtyre vdekjeve jan\u00eb t\u00eb parandalueshme, dhe shum\u00eb lloje kanceri, n\u00ebse zbulohen her\u00ebt, jan\u00eb t\u00eb sh\u00ebruesh\u00ebm.<\/span><\/p>\n

Epidemia globale e kancerit \u00ebsht\u00eb e madhe dhe po rritet. Parashikohet q\u00eb t\u00eb kemi rritje me 19.3 milion\u00eb raste n\u00eb vit n\u00eb bot\u00eb deri n\u00eb vitin 2025, krahasuar me 14.1 milion\u00eb n\u00eb vitin 2012. N\u00eb vendin ton\u00eb, bazuar n\u00eb t\u00eb dh\u00ebnat e Regjistrit Komb\u00ebtar t\u00eb Kancerit, \u00e7do vit n\u00eb Shqip\u00ebri shfaqen rreth 6000 raste t\u00eb reja me tumore. Ato shkaktojn\u00eb mbi 16% t\u00eb t\u00eb gjitha vdekjeve (shkaku i dyt\u00eb kryesor pas s\u00ebmundjeve kardiovaskulare n\u00eb vitet pas Covid-19).<\/span><\/p>\n

\u00c7do vit prej tumoreve humbin jet\u00ebn mbi 3600 persona. Rreth 10% e vdekjeve nga tumoret jan\u00eb n\u00ebn mosh\u00ebn 50 vje\u00e7. T\u00eb dh\u00ebnat zyrtare t\u00eb ISHP-s\u00eb tregojn\u00eb se, tumoret m\u00eb t\u00eb shpeshta jan\u00eb ai i mushk\u00ebrive, me rreth 800 raste t\u00eb reja dhe tumori i gjirit, me rreth 700 raste. Prirja e tumoreve n\u00eb sistemin sh\u00ebndet\u00ebsor shqiptar ka qen\u00eb n\u00eb rritje n\u00eb dekadat e fundit, kryesisht p\u00ebr arsye t\u00eb rritjes s\u00eb mosh\u00ebs mesatare t\u00eb popullat\u00ebs, por edhe p\u00ebr shkaqe t\u00eb tjera t\u00eb lidhura me stilin e jetes\u00ebs apo mjedisin. Kjo prirje \u00ebsht\u00eb shprehur sidomos n\u00eb nivelin e p\u00ebrdorimit t\u00eb sh\u00ebrbimeve sh\u00ebndet\u00ebsore lidhur me s\u00ebmundjet tumorale.<\/span><\/p>\n

Sipas studimit t\u00eb IQVIA, disponueshm\u00ebria mesatare e BE-s\u00eb \u00ebsht\u00eb 9% m\u00eb e lart\u00eb p\u00ebr produktet onkologjike, sesa t\u00eb gjitha produktet e miratuara. Vonesa mesatare nd\u00ebrmjet autorizimit n\u00eb treg dhe aksesit t\u00eb pacient\u00ebve p\u00ebr produktet e onkologjis\u00eb varion nga 3 muaj deri n\u00eb mbi 31 muaj, 2.5 vjet n\u00eb vende si Shqip\u00ebria.<\/span><\/p>\n

Vet\u00ebm Gjermania ka disponueshm\u00ebrin\u00eb e t\u00eb gjitha ila\u00e7eve onkologjike t\u00eb vitit t\u00eb fundit.<\/span><\/p>\n

\"\"<\/a><\/span><\/strong><\/p>\n

2017-2020, asnj\u00eb medikament i ri n\u00eb list\u00eb q\u00eb trajton s\u00ebmundjet e rralla<\/span><\/strong><\/p>\n

Barnat \u201cOrphan\u201d, ose ndryshe \u201cjetime\u201d, jan\u00eb t\u00eb destinuara p\u00ebr diagnostikimin, parandalimin ose trajtimin e s\u00ebmundjeve t\u00eb rralla k\u00ebrc\u00ebnuese p\u00ebr jet\u00ebn, q\u00eb prekin jo m\u00eb shum\u00eb se 5 n\u00eb 10,000 njer\u00ebz n\u00eb Europ\u00eb. Deri m\u00eb sot, Komisioni Europian ka autorizuar m\u00eb shum\u00eb se 200 ila\u00e7e \u201cjetime\u201d p\u00ebr t\u00eb mir\u00ebn e pacient\u00ebve q\u00eb vuajn\u00eb nga s\u00ebmundje t\u00eb rralla.\u00a0Sponsor\u00ebt p\u00ebrgjegj\u00ebs p\u00ebr k\u00ebto barna p\u00ebrfitojn\u00eb nga stimuj si heqja e tarifave p\u00ebr procedurat rregullatore dhe ekskluzivitet tregu 10-vje\u00e7ar p\u00ebr shkak t\u00eb p\u00ebrdorimit t\u00eb tyre t\u00eb kufizuar.<\/span><\/p>\n

Vet\u00ebm gjat\u00eb periudh\u00ebs 2017-2020, BE autorizoi edhe 57 medikamente q\u00eb trajtojn\u00eb s\u00ebmundjet e rralla. Vendet e zhvilluara, por edhe ato t\u00eb rajonit, kan\u00eb p\u00ebrfshir\u00eb n\u00eb listat e rimbursimit disa nga k\u00ebto medikamente, sipas kapacitetit financiar, nd\u00ebrsa Shqip\u00ebria nuk ka p\u00ebrfshir\u00eb asnj\u00eb nga k\u00ebto medikamente.<\/span><\/p>\n

Gjermania, Italia dhe Danimarka pranuan mbi 90% t\u00eb k\u00ebtyre barnave t\u00eb reja n\u00eb listat e tyre t\u00eb rimbursimit, pasi ato kan\u00eb nj\u00eb p\u00ebrdorim t\u00eb ngusht\u00eb, por kan\u00eb kosto dhe ndikim direkt n\u00eb jet\u00ebgjat\u00ebsin\u00eb e pacientit. S\u00ebmundjet e rralla shfaqen q\u00eb f\u00ebmij\u00ebri, por edhe m\u00eb von\u00eb.<\/span><\/p>\n

P.sh. \u201cSkleroza Multiple\u201d, \u00ebsht\u00eb s\u00ebmundje q\u00eb prek trurin dhe palc\u00ebn kurrizore, simptomat e s\u00eb cil\u00ebs nisin me \u00e7rregullimin e shikimit, dhembje t\u00eb gjymtyr\u00ebve, v\u00ebshtir\u00ebsi n\u00eb koordinim, dob\u00ebsim t\u00eb muskujve, lodhje, etj.<\/span><\/p>\n

N\u00eb Shqip\u00ebri, ka qindra t\u00eb prekur, por deri m\u00eb tani nuk ka asnj\u00eb terapi n\u00eb rimbursim p\u00ebr trajtimin e saj. Shoqata e Farmacist\u00ebve pohoi se, disa medikamente q\u00eb p\u00ebrdoren p\u00ebr k\u00ebt\u00eb s\u00ebmundje n\u00eb Shqip\u00ebri jan\u00eb shum\u00eb t\u00eb vjetra, nd\u00ebrkoh\u00eb q\u00eb terapi t\u00eb reja po aplikohen \u00e7do dit\u00eb p\u00ebr k\u00ebt\u00eb s\u00ebmundje, e cila po p\u00ebrhapet m\u00eb shum\u00eb si pasoj\u00eb e faktor\u00ebve mjedisor\u00eb.<\/span><\/p>\n

Shqip\u00ebria \u00ebsht\u00eb i vetmi vend n\u00eb Europ\u00eb q\u00eb nuk p\u00ebrfshiu n\u00eb list\u00ebn e saj t\u00eb rimbursimit medikamente t\u00eb reja p\u00ebr s\u00ebmundjet e rralla, nd\u00ebrkoh\u00eb q\u00eb Serbia miratoi dhe p\u00ebrfshiu n\u00eb list\u00ebn e rimbursimit tre nga barnat \u201cOrphan\u201d dhe Maqedonia e Veriut dhe Bosnja, pranuan nga 1 terapi secila.<\/span><\/p>\n

\"\"<\/a><\/span><\/strong><\/p>\n

Shqip\u00ebria, akses t\u00eb kufizuar n\u00eb terapi inovatove mjek\u00ebsore<\/span><\/strong><\/p>\n

Tregu shqiptar \u00ebsht\u00eb n\u00eb zhvillim e sip\u00ebr, ku barnat tradicionale gjenerike dhe ato jasht\u00eb patent\u00ebs p\u00ebrfaq\u00ebsojn\u00eb 76%. Nj\u00eb studim tjet\u00ebr i vitit 2021 i IQVIA gjeti se, konsumi i ila\u00e7eve p\u00ebr frym\u00eb \u00ebsht\u00eb 35 euro n\u00eb Shqip\u00ebri, kur n\u00eb vendet e Adriatikut, \u00ebsht\u00eb 158 euro.<\/span><\/p>\n

N\u00eb list\u00ebn shqiptare t\u00eb rimbursimit jan\u00eb vet\u00ebm 255 molekula, nd\u00ebrsa n\u00eb vendet e Adriatikut, 962 molekula. Kardiologjia p\u00ebrfaq\u00ebson 24% t\u00eb vler\u00ebs s\u00eb shpenzuar n\u00eb Shqip\u00ebri, kur n\u00eb vendet e tjera onkologjia z\u00eb 19 \u2013 25% t\u00eb totalit. N\u00eb Shqip\u00ebri, onkologjia, pjesa e rimbursimit, p\u00ebrfaq\u00ebson vet\u00ebm 15%.<\/span><\/p>\n

Klasa m\u00eb e zhvilluar \u00ebsht\u00eb kardiologjia me 62 molekula t\u00eb rimbursuara nga 80 molekula n\u00eb vendet e Adriatikut (77%). Shqip\u00ebria ka ende nj\u00eb hendek t\u00eb madh n\u00eb konsumin e barnave kardiologjike p\u00ebr frym\u00eb rreth 48%, kundrejt vendeve t\u00eb Adriatikut.<\/span><\/p>\n

Hendeku m\u00eb i madh v\u00ebrehet n\u00eb onkologji ku vet\u00ebm 40 nga 165 (24%) molekula rimbursohen me hendek 75% ndaj konsumit t\u00eb Adriatikut p\u00ebr frym\u00eb.<\/span><\/p>\n

 <\/p>\n

Fondet p\u00ebr sh\u00ebndet\u00ebsin\u00eb rriten, por rimbursimi n\u00eb vendnum\u00ebro<\/span><\/strong><\/p>\n

Buxheti i Fondit t\u00eb Sigurimit Sh\u00ebndet\u00ebsor \u00ebsht\u00eb rritur vit pas viti, por ritmet e rritjes nuk kan\u00eb qen\u00eb t\u00eb nj\u00ebjta p\u00ebr fondin e rimbursimit t\u00eb medikamenteve. N\u00eb vitin 2019, fondet p\u00ebr rimbursimin e barnave zinin 27% t\u00eb buxhetit total t\u00eb Fondit t\u00eb Sigurimeve Sh\u00ebndet\u00ebsore, nd\u00ebrsa n\u00eb vitin 2021, 23% t\u00eb buxhetit total t\u00eb sigurimeve.<\/span><\/p>\n

N\u00eb vitin 2022 ato jan\u00eb planifikuar 20%, edhe pse lista e barnave t\u00eb rimbursueshme \u00ebsht\u00eb zgjeruar dhe n\u00eb skem\u00eb p\u00ebrfshihen edhe mjekimet p\u00ebr t\u00eb s\u00ebmur\u00ebt me Covid-19. N\u00eb vitin 2013, fondet p\u00ebr rimbursimin e barnave zinin 28% t\u00eb totalit t\u00eb buxhetit t\u00eb sigurimeve sh\u00ebndet\u00ebsore.<\/span><\/p>\n

Buxheti i Fondit t\u00eb Sigurimeve t\u00eb Detyrueshme Sh\u00ebndet\u00ebsore (FSDKSH) \u00ebsht\u00eb rritur vit pas viti, por rritja m\u00eb s\u00eb shumti ka shkuar p\u00ebr financimin e kontratave me Partneritet Publik-Privat si kontrolli mjek\u00ebsor baz\u00eb (check-up, sterilizimi i mjeteve kirurgjikale, dializa dhe s\u00eb fundmi laboratori). N\u00eb vitin 2020, shpenzimet p\u00ebr pagesat e koncesioneve zun\u00eb 4.6% t\u00eb shpenzimeve totale t\u00eb Fondit t\u00eb Sigurimeve, me ulje n\u00eb raport me vitin 2018 dhe 2019, kur ato zun\u00eb 6 dhe 6.9% t\u00eb totalit t\u00eb shpenzimeve t\u00eb fondit. Ulja erdhi p\u00ebr shkak t\u00eb pezullimit t\u00eb p\u00ebrkohsh\u00ebm t\u00eb koncesionit t\u00eb Check-Up.<\/span><\/p>\n

Sipas t\u00eb dh\u00ebnave t\u00eb Organizat\u00ebs Bot\u00ebrore t\u00eb Sh\u00ebndet\u00ebsis\u00eb, Shqip\u00ebria mbulon vet\u00ebm 70% t\u00eb popullsis\u00eb s\u00eb saj nga Fondi i Sigurimit t\u00eb Detyruesh\u00ebm. Boshll\u00ebku i Shqip\u00ebris\u00eb n\u00eb mbulimin e popullsis\u00eb lidhet me buxhetin e ul\u00ebt t\u00eb Skem\u00ebs s\u00eb Sigurimeve Sh\u00ebndet\u00ebsore t\u00eb Detyrueshme. P\u00ebrve\u00e7se ka mbulimin m\u00eb t\u00eb ul\u00ebt t\u00eb popullsis\u00eb, Shqip\u00ebria nuk i ka n\u00eb skem\u00ebn e sigurimeve sh\u00ebrbimet dentare.<\/span><\/p>\n

Mbulimi i ul\u00ebt i popullsis\u00eb nga sigurimi i detyruesh\u00ebm lidhet me nivelin e lart\u00eb t\u00eb informalitetit n\u00eb vend. Rreth nj\u00eb e treta e popullsis\u00eb \u00ebsht\u00eb e pasiguruar dhe duhet t\u00eb paguaj\u00eb pothuajse t\u00eb gjitha sh\u00ebrbimet sh\u00ebndet\u00ebsore nga xhepi.<\/span><\/p>\n

T\u00eb pasiguruarit paguajn\u00eb koston e plot\u00eb t\u00eb analizave diagnostike, barnave dhe kujdesit t\u00eb specializuar jourgjent, nd\u00ebrsa t\u00eb siguruarit paguajn\u00eb bashk\u00ebpages\u00eb deri n\u00eb 50% t\u00eb \u00e7mimit t\u00eb referenc\u00ebs p\u00ebr barnat me recet\u00eb ambulatore.<\/span><\/p>\n

\"\"<\/a><\/span><\/strong><\/p>\n

Duhet plan afatgjat\u00eb financimi<\/span><\/strong><\/p>\n

Studimet nd\u00ebrkomb\u00ebtare t\u00eb IQVIA k\u00ebshilloj\u00eb se Shqip\u00ebris\u00eb i duhen buxhete t\u00eb ve\u00e7anta dhe nj\u00eb plan afatgjat\u00eb q\u00eb t\u00eb zbatohet p\u00ebr barnat tradicionale, ato t\u00eb patentuara jasht\u00eb, terapit\u00eb e reja, barnat e shtrenjta p\u00ebr fush\u00ebn e onkologjis\u00eb dhe barnat p\u00ebr s\u00ebmundjet e rralla.<\/span><\/p>\n

Numri i molekulave q\u00eb mungojn\u00eb ende n\u00eb list\u00ebn shqiptare t\u00eb rimbursimit tregon nevoj\u00ebn e nj\u00eb analize t\u00eb boshll\u00ebqeve dhe p\u00ebrgatitje m\u00eb e fuqishme e mb\u00ebshtetur nga planifikimi buxhetor. Gjithashtu IQVIA sugjeron q\u00eb, mjedisi ligjor t\u00eb mb\u00ebshtes\u00eb aksesin n\u00eb rritjen n\u00eb terapit\u00eb e reja, n\u00eb thjeshtimin e kuadrit rregullator dhe provat klinike, etj.<\/span><\/p>\n

P\u00ebr shkak t\u00eb munges\u00ebs s\u00eb aft\u00ebsis\u00eb financiare, Shqip\u00ebria duhet t\u00eb marr\u00eb n\u00eb konsiderat\u00eb nivele t\u00eb ndryshme t\u00eb bashk\u00ebpages\u00ebs s\u00eb pacientit p\u00ebr terapi t\u00eb shtrenjta.<\/span><\/p>\n

VINI RE:<\/span> Ky artikull \u00ebsht\u00eb pron\u00eb intelektuale e Monitor.al<\/a><\/span><\/span><\/strong><\/p>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"excerpt":{"rendered":"

Kanceri dhe s\u00ebmundjet e rralla \u201cvrasin\u201d mij\u00ebra persona gjat\u00eb nj\u00eb viti, edhe p\u00ebr shkak se, Shqip\u00ebria nuk ka akses n\u00eb terapit\u00eb e reja inovative q\u00eb trajtojn\u00eb k\u00ebto s\u00ebmundje. Nga viti 2017 deri n\u00eb vitin 2020, Shqip\u00ebria p\u00ebrfshiu n\u00eb list\u00ebn e rimbursimit vet\u00ebm 5 barna t\u00eb reja nga 160 t\u00eb tilla q\u00eb hyn\u00eb n\u00eb p\u00ebrdorim n\u00eb […]<\/p>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"author":30,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[65,13],"tags":[],"class_list":["post-550960","post","type-post","status-publish","format-standard","hentry","category-lajme","category-te-fundit"],"gt_translate_keys":[{"key":"link","format":"url"}],"_links":{"self":[{"href":"https:\/\/www.hashtag.al\/index.php\/wp-json\/wp\/v2\/posts\/550960","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hashtag.al\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hashtag.al\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hashtag.al\/index.php\/wp-json\/wp\/v2\/users\/30"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hashtag.al\/index.php\/wp-json\/wp\/v2\/comments?post=550960"}],"version-history":[{"count":0,"href":"https:\/\/www.hashtag.al\/index.php\/wp-json\/wp\/v2\/posts\/550960\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hashtag.al\/index.php\/wp-json\/wp\/v2\/media?parent=550960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hashtag.al\/index.php\/wp-json\/wp\/v2\/categories?post=550960"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hashtag.al\/index.php\/wp-json\/wp\/v2\/tags?post=550960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}